Lars Fogh Iversen

Lars Fogh Iversen

Auto-generated profile, based on publicly available information

Lars Fogh Iversen

Protein Chemistry, Novo Nordisk, DK-2880 Bagsvaerd, Denmark

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LILars Fogh Iversen
Lars Fogh Iversen
HAHenrik Sune Andersen
Henrik Sune Andersen
SBSven Branner
Sven Branner
SMSteen B. Mortensen
Steen B. Mortensen
GPGünther H. J. Peters
Günther H. J. Peters
NMNiels Peter Hundahl Møller
Niels Peter Hundahl Møller
Several protein-tyrosine phosphatases (PTPs) have been proposed to act as negative regulators of insulin signaling. Recent studies have shown increased insulin sensitivity and resistance to obesity in PTP1B knockout mice, thus pointing to this enzyme as a potential drug target in diabetes. Structure-based design, guided by PTP mutants and x-ray protein crystallography, was used to optimize a relatively weak, nonphosphorus, nonpeptide general PTP inhibitor (2-(oxalyl-amino)-benzoic acid) into a highly selective PTP1B inhibitor. This was achieved by addressing residue 48 as a selectivity determining residue. By introducing a basic nitrogen in the core structure of the inhibitor, a salt bridge was formed to Asp-48 in PTP1B. In contrast, the basic nitrogen causes repulsion in other PTPs containing an asparagine in the equivalent position resulting in a remarkable selectivity for PTP1B. Importantly, this was accomplished while retaining the molecular weight of the inhibitor below 300 g/mol.

1 January 1999 in Protein Science
Verified
Journal Article
Open access
PDF file
LIL. F. Iversen
L. F. Iversen
JKJ. S. Kastrup
J. S. Kastrup
SBS. E. Bjørn
S. E. Bjørn
FWF. C. Wiberg
F. C. Wiberg
ILI. K. Larsen
I. K. Larsen
PRP. B. Rasmussen
P. B. Rasmussen
The three N‐glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng‐HBP) mutant. ng‐HBP has been crystallized and tested for biological activity. Complete X‐ray data have been collected to 2.1 Å resolution, and the structure has been fully refined to an R‐factor of 18.4% (Rfree 27.7%). The ng‐HBP structure reveals that neither the secondary nor tertiary structure have changed due to the removal of the glycosylation, as compared to the previously determined glycosylated HBP structure. Although the primary events in N‐linked glycosylation occurs concomitant with polypeptide synthesis and therefore possesses the ability to influence early events in protein folding, we see no evidence of glycosylation influencing the structure of the protein. The root‐mean‐square deviation between the superimposed structures was 0.24 Å (on Cα atoms), and only minor local structural differences are observed. Also, the overall stability of the protein seems to be unaffected by glycosylation, as judged by the B‐factors derived from the two X‐ray structures. The flexibility of a glycan site may be determined by the local polypeptide sequence and structure rather than the glycan itself. The biological in vitro activity assay data show that ng‐HBP, contrary to glycosylated HBP, mediates only a very limited stimulation of the lipopolysaccharide induced cytokine release from human monocytes. In animal models of fecal peritonitis, glycosylated HBP treatment rescues mice from and an otherwise lethal injury. It appears that ng‐HBP have significant effect on survival, and it can be concluded that ng‐HBP can stimulate the host defence machinery albeit to a lesser extent than glycosylated HBP.